Advertisement

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia

Benjamin L. Lampson, Haesook T. Kim, Matthew S. Davids, Jeremy S. Abramson, Arnold S. Freedman, Caron A. Jacobson, Philippe A. Armand, Robin M. Joyce, Jon E. Arnason, Laura Z. Rassenti, Thomas J. Kipps, Joshua Fein, Stacey M. Fernandes, John R. Hanna, David C. Fisher and Jennifer R. Brown

Article Information

Citation 
vol. 3 no. 7 1167-1174
PubMed 

Print ISSN 
Online ISSN 
History 
  • Submitted December 19, 2018
  • Accepted February 8, 2019
  • Published online April 9, 2019.


Contributors 
  • Benjamin L. Lampson, 1Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA;
  • Haesook T. Kim, 2Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA;
  • Matthew S. Davids, 1Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA;
  • Jeremy S. Abramson, 3Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA;
  • Arnold S. Freedman, 1Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA;
  • Caron A. Jacobson, 1Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA;
  • Philippe A. Armand, 1Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA;
  • Robin M. Joyce, 4Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA; and
  • Jon E. Arnason, 4Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, MA; and
  • Laura Z. Rassenti, 5Division of Hematology/Oncology, Department of Medicine, University of California, San Diego, La Jolla, CA
  • Thomas J. Kipps, 5Division of Hematology/Oncology, Department of Medicine, University of California, San Diego, La Jolla, CA
  • Joshua Fein, 1Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA;
  • Stacey M. Fernandes, 1Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA;
  • John R. Hanna, 1Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA;
  • David C. Fisher, 1Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA;
  • Jennifer R. Brown, 1Division of Hematologic Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA;

Altmetric.com Statistics

The Altmetric score is a weighted count of online attention designed to reflect the volume and reach of online engagement surrounding an individual research output